Table 4.
Overlapping MOGAD/positive MOG-IgG and cancers or paraneoplastic syndromes
| Reference | Number of cases | Sex/age | MOG-IgG-associated clinical phenotype | Overlapping cancer/paraneoplastic syndrome |
|---|---|---|---|---|
| Kwon et al. (2020)133 | 1 | F/64 | MOG-EM | T-cell lymphoma |
| Li et al. (2020)134 | 1 | F/49 | MOG-EM | Lung adenocarcinoma |
| Cohen et al. (2020)135 | 1 | F/52 | MOGAD | Colon adenocarcinoma |
| Kwon et al. (2020)136 | NA | NA | MOG-EM | From 63 patients with MOG-EM, 11.3% had a history of cancer, and 6.5% had concurrent cancer. Types of cancers not specified. |
| Ajam et al. (2020)137 | 1 | M/25 | MOG-ON | Meningioma |
| Delgado et al. (2021)138 | 1 | F/37 | MOG-ON | Pituitary macroadenoma |
| Cirkel et al. (2021)139 | 1 | F/44 | MOG-EM | Paraneoplastic encephalomyeloradiculits with multiple
autoantibodies against ITPR-1, GFAP, and MOG Underlying malignancy: borderline tumor of the ovary |
| Cherian et al. (2021)140 | 1 | F/37 | MOG-LETM | MOG-LETM as paraneoplastic myelopathy Underlying malignancy: breast carcinoma |
| Rodenbeck et al. (2021)141 | 1 | F/64 | MOG-MY | MOG-MY as paraneoplastic myelopathy Underlying malignancy: lung adenocarcinoma |
Abbreviations: EM: encephalomyelitis; ON: optic neuritis; LETM: longitudinally extensive transverse myelitis; MY: myelitis